Curiously, we found the yet poorly explored gene FCGR2A (associated with transcript FCGR2A-201 found in our signature) as a predicted successful target for drugs such as SM-101 in non-cancer diseases like Idiopathic thrombocytopenic purpura (78), according to the Therapeutic Target Database (TTD) (28). The gene discussed is FCGR2A; the disease is autoimmune thrombocytopenic purpura.